- Home
- OUST vs NTLA Comparison
OUST vs NTLA Comparison
Compare OUST & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OUST
- NTLA
- Stock Information
- Founded
- OUST 2015
- NTLA 2014
- Country
- OUST United States
- NTLA United States
- Employees
- OUST N/A
- NTLA N/A
- Industry
- OUST Industrial Machinery/Components
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- OUST Technology
- NTLA Health Care
- Exchange
- OUST Nasdaq
- NTLA Nasdaq
- Market Cap
- OUST 1.1B
- NTLA 1.2B
- IPO Year
- OUST N/A
- NTLA 2016
- Fundamental
- Price
- OUST $28.95
- NTLA $11.42
- Analyst Decision
- OUST Strong Buy
- NTLA Buy
- Analyst Count
- OUST 6
- NTLA 20
- Target Price
- OUST $23.83
- NTLA $32.30
- AVG Volume (30 Days)
- OUST 2.3M
- NTLA 4.1M
- Earning Date
- OUST 11-06-2025
- NTLA 11-06-2025
- Dividend Yield
- OUST N/A
- NTLA N/A
- EPS Growth
- OUST N/A
- NTLA N/A
- EPS
- OUST N/A
- NTLA N/A
- Revenue
- OUST $125,848,000.00
- NTLA $52,857,000.00
- Revenue This Year
- OUST $33.30
- NTLA $8.32
- Revenue Next Year
- OUST $36.50
- NTLA N/A
- P/E Ratio
- OUST N/A
- NTLA N/A
- Revenue Growth
- OUST 26.37
- NTLA 14.99
- 52 Week Low
- OUST $5.91
- NTLA $5.90
- 52 Week High
- OUST $36.25
- NTLA $23.76
- Technical
- Relative Strength Index (RSI)
- OUST 51.53
- NTLA 50.54
- Support Level
- OUST $27.68
- NTLA $10.89
- Resistance Level
- OUST $31.10
- NTLA $12.03
- Average True Range (ATR)
- OUST 2.03
- NTLA 0.63
- MACD
- OUST -0.21
- NTLA 0.02
- Stochastic Oscillator
- OUST 39.87
- NTLA 33.97
About OUST Ouster Inc.
Ouster Inc is a provider of lidar sensors for the automotive, industrial, robotics, and smart infrastructure industries. Ouster's products include high-resolution scanning and solid-state digital lidar sensors, Velodyne Lidar sensors, and software solutions. The company operates in the Americas, Asia and Pacific, Europe, Middle East, and Africa regions. It derives maximum revenue from Americas.
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.